Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13246MR)

This product GTTS-WQ13246MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13246MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14895MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ6578MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ3426MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ494MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ10175MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ6766MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ2268MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ5268MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW